关注
John Heymach
John Heymach
Chair, Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center
在 mdanderson.org 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Comprehensive molecular profiling of lung adenocarcinoma
Cancer Genome Atlas Research Network
Nature 511 (7511), 543, 2014
38592014
Comprehensive genomic characterization of squamous cell lung cancers
Cancer Genome Atlas Research Network
Nature 489 (7417), 519, 2012
36762012
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
12822018
Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional …
DR Gomez, C Tang, J Zhang, GR Blumenschein Jr, M Hernandez, JJ Lee, ...
Journal of Clinical Oncology 37 (18), 1558, 2019
10472019
The BATTLE trial: personalizing therapy for lung cancer
ES Kim, RS Herbst, II Wistuba, JJ Lee, GR Blumenschein Jr, A Tsao, ...
Cancer discovery 1 (1), 44-53, 2011
10362011
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic …
DR Gomez, GR Blumenschein, JJ Lee, M Hernandez, R Ye, DR Camidge, ...
The lancet oncology 17 (12), 1672-1682, 2016
10272016
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
J Zhang, J Fujimoto, J Zhang, DC Wedge, X Song, J Zhang, S Seth, ...
Science 346 (6206), 256-259, 2014
10252014
An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor …
LA Byers, L Diao, J Wang, P Saintigny, L Girard, M Peyton, L Shen, Y Fan, ...
Clinical cancer research 19 (1), 279-290, 2013
10162013
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
L Chen, DL Gibbons, S Goswami, MA Cortez, YH Ahn, LA Byers, X Zhang, ...
Nature communications 5 (1), 5241, 2014
9302014
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
CM Rudin, JT Poirier, LA Byers, C Dive, A Dowlati, J George, JV Heymach, ...
Nature Reviews Cancer 19 (5), 289-297, 2019
8632019
Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network
E Collisson, J Campbell, A Brooks, A Berger, W Lee, J Chmielecki, D Beer, ...
Nature 511 (7511), 543-550, 2014
8332014
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, ...
Cancer research 67 (24), 11924-11932, 2007
8332007
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic …
F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ...
Cancer discovery 5 (8), 860-877, 2015
7962015
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
F Skoulidis, JV Heymach
Nature Reviews Cancer 19 (9), 495-509, 2019
7152019
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
PK Paik, E Felip, R Veillon, H Sakai, AB Cortot, MC Garassino, J Mazieres, ...
New England Journal of Medicine 383 (10), 931-943, 2020
6702020
Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer
T Sen, BL Rodriguez, L Chen, CMD Corte, N Morikawa, J Fujimoto, ...
Cancer discovery 9 (5), 646-661, 2019
6462019
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
NT Ihle, LA Byers, ES Kim, P Saintigny, JJ Lee, GR Blumenschein, A Tsao, ...
Journal of the National Cancer Institute 104 (3), 228-239, 2012
5632012
A pan-cancer proteomic perspective on The Cancer Genome Atlas
R Akbani, PKS Ng, HMJ Werner, M Shahmoradgoli, F Zhang, Z Ju, W Liu, ...
Nature communications 5 (1), 3887, 2014
5562014
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
CM Gay, CA Stewart, EM Park, L Diao, SM Groves, S Heeke, BY Nabet, ...
Cancer cell 39 (3), 346-360. e7, 2021
5482021
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with …
S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ...
Journal of clinical oncology 28 (3), 453, 2010
5392010
系统目前无法执行此操作,请稍后再试。
文章 1–20